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Available online 2 March 2016Introduction: Soil-transmitted helminth (STH) infections are predominately controlled by provid-
ing children with preventive chemotherapy with either albendazole or mebendazole. However,
neither has a high efﬁcacy against Trichuris trichiura. This low efﬁcacy limits the overall effective-
ness of the current STH control programmes against T. trichiura. It has been demonstrated that
co-administering ivermectin with albendazole or mebendazole signiﬁcantly increases the efﬁcacy
of current treatments, which may increase the overall effectiveness of control programmes.
Methods: Using a STH transmission mathematical model, we evaluated the potential impact of co-
administering ivermectin with albendazole or mebendazole to treat T. trichiurawithin a preventive
chemotherapy programme targeting children (2–15 year olds).We evaluated the impact in terms of
reduction in prevalent infections, mean worm burden, and prevalence of heavy infections.
Results: Although the current treatment strategy reduced T. trichiura worm burden and preva-
lence of heavy infections, due to their poor efﬁcacy the long term impact of preventive chemo-
therapy for children was smaller compared to the other STH. Co-administering ivermectin
increased the projected impact of the preventive chemotherapy programme in terms of all
three of the explored metrics, practically in high transmission settings. Furthermore, ivermectin
co-administration greatly increased the feasibility of and timeframe for breaking transmission.
Conclusions: Co-administering ivermectin notably increased the projected impact of preventive che-
motherapy in high transmission settings and increased the feasibility for breaking transmission. This
has important implications for control programmes, some of which may be shifting focus frommor-
bidity control to interruption of transmission, and someofwhichmay be logistically unable to provide
preventive chemotherapy twice a year as recommended. However, the beneﬁt of co-administering
ivermectin is limited by the fact that 2–5 year olds are often ineligible to receive treatment.
© 2016 The Authors. Published by Elsevier Ltd on behalf of World Federation of
Parasitologists. This is an open access article under the CC BY license
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The most common neglected tropical diseases (NTDs) are the soil-transmitted helminths (STH) which include Ascaris
lumbricoides, Trichuris trichiura and the hookworms (Pullan and Brooker, 2012). The mainstay of the control of STH is regular
preventive chemotherapy using either albendazole or mebendazole. Control programmes largely target these treatments at
school-aged children (SAC) and preschool-aged children (Pre-SAC). In the majority of endemic areas, treatment is given annually,
but in areas of intense transmission (deﬁned as a prevalence of any STH greater than 50% in SAC), the WHO recommends that the
treatment frequency is increased to at least twice a year (depending on resource availability) (World Health Organization, 2006).
The aim of these WHO guidelines is to reduce the prevalence of heavy infections and their associated morbidity (World Health
Organization, 2012).
However, although both albendazole and mebendazole have a high efﬁcacy against A. lumbricoides (with cure rates above
78%), mebendazole does not effectively clear hookworm infections, and neither drug has an adequate efﬁcacy against
T. trichiura (Keiser and Utzinger, 2008; Vercruysse et al., 2011a; Levecke et al., 2014a) (albendazole has a cure rate of 28% (95%
CI: 13%–39%) and mebendazole 36% (95% CI: 16%–51%) (Keiser and Utzinger, 2008)). This considerably lower efﬁcacy of the stan-
dard treatments limits the overall possible effectiveness of preventive chemotherapy against T. trichiura, which is estimated to in-
fect 464.6 million people worldwide (mainly in sub-Saharan Africa and Asia but also in parts of Latin America (Pullan et al.,
2014a)). Heavy T. trichiura infections can lead to severe anaemia, growth retardation, and impaired cognitive development
(Bundy and Cooper, 1989). In addition to these clinical and nutritional impacts, T. trichiuramay have effects on the physical ﬁtness
of children (Yap et al., 2014).
In addition to the goals of reducing morbidity, there is growing interest in investigating the feasibility of interrupting transmis-
sion of STH (Bill & Melinda Gates Foundation. 2014; Brooker et al., 2015; Anderson et al., 2015) — although this is not yet the aim
of current World Health Organisation (WHO) policy. In this regard, the poor treatment efﬁcacy of albendazole and mebendazole
against T. trichiura may hinder the success of STH elimination programmes as a whole — as residual T. trichiura infection may re-
main after the transmission of A. lumbricoides and hookworm is interrupted.
The impact of a STH control programme on T. trichiura may be enhanced by adding ivermectin to the treatment schedule. This
approach has been demonstrated to signiﬁcantly increase the treatment efﬁcacy of both standalone albendazole and mebendazole
against T. trichiura (Knopp et al., 2010; Beach et al., 1999; Belizario, 2003; Speich et al., 2015). Ivermectin is an anthelmintic which
Merck & Co donate for the control of onchocerciasis and lymphatic ﬁlariasis (25 Years: The MECTIZANⓇ Donation Program).
In this paper we use mathematical models of STH transmission (Truscott et al., 2014, 2015; Anderson et al., 2014; Turner et al.,
Epub ahead of print) to evaluate the following factors; 1) the additional programmatic impact gained by co-administering iver-
mectin in terms of reducing mean worm burden, prevalent infections, and the prevalence of heavy infections; and 2) how iver-
mectin co-administration may inﬂuence the feasibility of interrupting the transmission of T. trichiura.
2. Methods
This analysis was performed using a fully age-structured deterministic model of the dynamics of STH transmission including
simulation of parasite sexual reproduction (Truscott et al., 2014, 2015; Anderson et al., 2014; Turner et al., Epub ahead of
print). In this paper we used the model parameters pertaining to T. trichiura which are described in more detail in the Supporting
Table S1. It should be noted that the individuals treated each round are effectively chosen at random from the relevant age
group(s) and the model does not currently address systematic non-compliance. A future publication will examine this issue in
more detail using an individual-based stochastic model.
2.1. Fitted setting
The model parameters describing the age-speciﬁc exposure and contribution to the infection reservoir and level of transmis-
sion (R0) were estimated by ﬁtting to data from the cross-sectional study of T. trichiura conducted in St. Lucia by Bundy et al.
(1987) (Fig. 1). The study collected pre-treatment and post-treatment stool samples from 119 individuals across a full range of
ages. The resulting data set contains a record for each individual consisting of age, eggs per gramme (EPG) of faeces and expelled
worm burden. We estimated that in this setting, the overall R0 for the whole community was 1.75 (reported R0 estimates for
T. trichiura often relate to the R0 for children only and are therefore higher).
The age proﬁle of infection intensity (Fig. 1) is very consistent to that reported by a recent systematic review of epidemiolog-
ical surveys of STH in Southeast Asia (Dunn et al., 2016).
2.2. Treatment efﬁcacy
The model describes changes in the mean worm burden over time and age. Treatment impact within the model is deﬁned in
terms of the proportion of worms expelled after treatment. The efﬁcacy values used (see below) are based on observed faecal egg
reduction rates (ERRs) and not cure rates (the percentage of individuals who became helminth egg negative following treatment
with an anthelmintic drug). The ERR of standalone albendazole (400 mg) was assumed to be 50% (Vercruysse et al., 2011a) and
the ERR of albendazole–ivermectin co-administration was assumed to be 95%, based on a recent randomized controlled trial by
Speich et al. (2015). This is consistent with a different trial which reported a similar ERR of 91% (Knopp et al., 2010). The impact
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Within this scenario, the ERR of standalone mebendazole (500 mg) was assumed to be 63% (Levecke et al., 2014a) and
mebendazole–ivermectin co-administration to be 97%, based on the trial by Knopp et al. (2010).
Children under 15 kg in weight or 90 cm in height (generally under ﬁve years of age (Goldman et al., 2007)) are ineligible to
receive ivermectin (World Health Organization, 2006) and were assumed to have only received albendazole or mebendazole. In-
dividuals under one years of age were assumed to be ineligible for mebendazole treatment and individuals under two years of age
ineligible for albendazole (400 mg) treatment. Though one year olds are sometimes provided a lower dose of albendazole
(200 mg) (World Health Organization, 2006), this was not included in the model as the precise efﬁcacy of this lower dose is
unknown.
2.3. Programmatic scenarios and output
The model was used to simulate a programme targeting Pre-SAC and SAC, following WHO guidelines (World Health
Organization 2012), and to compare standalone treatment to ivermectin co-administration using three different effectiveness met-
rics (described in Turner et al.'s (Epub ahead of print) work): 1) the total number of worm years averted (i.e. a year lived with a
worm), 2) the total number of prevalent infection case years averted (i.e. the number of years lived with a prevalent infection
prevented — not adjusted for diagnostic sensitivity), and 3) total number of heavy infection case years averted (i.e. the number
of years lived with heavy infection prevented). Heavy infection was deﬁned as having a worm burden above the age-speciﬁc
thresholds for disease described in Table 1 (as deﬁned in Chan et al.'s (1994) work and the 2010 Global Burden of Disease
study (Pullan et al., 2014a)). It is important to note that the relationships between STH infection burdens (present and/or past)
and morbidity are complex and not well understood (Brooker, 2010). We employed published estimates as detailed in Table 1.
In addition to the ﬁtted transmission setting (R0 = 1.75), we also explored a setting with lower transmission (R0 = 1.25).
These stratiﬁcations for transmission settings differ somewhat from the WHO prevalence categories for reasons described in
Truscott et al.'s (2014) work. These R0's are different to previous studies on hookworm and A. lumbricoides (Truscott et al.,
2014, 2015; Anderson et al., 2014; Turner et al., Epub ahead of print) due to the difference in the level of density dependence
acting on female worm fecundity (Supporting Table S1). The sensitivity of the relative impact of ivermectin co-administration
to different treatment coverage levels was also explored.
In addition to the increased programmatic impact regarding control of T. trichiura, the model was used to compare the feasi-
bility of breaking transmission for each of the different treatment regimens, as well as the timespans required to do so. Breaking
transmission is theoretically possible when worm levels are driven low enough that the probability of a female worm not encoun-
tering a mate in its host crosses a critical value. Below this, fertile egg production falls so low that the parasite population as a
whole cannot be sustained (the so called ‘breakpoint’, Anderson and May, 1985).
3. Results
3.1. Controlling morbidity
When using standalone albendazole (monotherapy), annual targeted PC (Pre-SAC and SAC) elicited only a gradual reduction in
the overall mean worm burden of T. trichiura (Fig. 2).
In lower transmission settings annual albendazole monotherapy at a high coverage (75%) was projected to be sufﬁcient in con-
trolling heavy infections in children (Fig. 3 and Supporting Fig. S2). However, these simulations indicate that in the ﬁtted (higher)Fig. 1. Model ﬁt to cross-sectional data from the St. Lucia study (Bundy et al., 1987). Note that the model ﬁt was done to the individual data points and not the
average data values shown here (see Supporting Information and Supporting Fig. 1).
Table 1
Age-speciﬁc worm burden thresholds for heavy infections (a proxy for morbidity) (Chan et al., 1994; Bundy et al., 2004).
Age class (years) Number of worms — lower threshold Number of worms — higher threshold
0–4 90 250
5–9 130 375
10+ 180 500
The lower thresholds are based on empirical observations of worm numbers associated with developmental deﬁcits (Chan et al., 1994). The higher thresh-
olds are more conservative values intended to reﬂect more serious clinical consequences and to provide a lower boundary to the estimate of morbidity (Chan
et al., 1994; Bundy et al., 2004).
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(Fig. 3 and Supporting Fig. S2). The impact of albendazole monotherapy on heavy infections was greater, the higher the intensity
threshold for heavy infection (Fig. 3 and Supporting Fig. S2).
Ivermectin co-administration increased the projected impact of the programme in terms of all three of the explored metrics;
worm burden, prevalent case years, and heavy infection case years, especially in high transmission settings (Table 2). Of particular
note, in a high transmission setting co-administering ivermectin increased the number of heavy infection case years averted by
36% (when using the lower intensity threshold (Table 1)). Although, some heavy infections may remain if treatment is only
given annually (Fig. 3).
If ivermectin (or another alternative treatment) could be given to Pre-SAC, the relative impact on heavy infections averted in
a high transmission setting would further increase from 36% to 52% (Fig. 4 and Supporting Fig. S3) — when using the lower in-
tensity threshold (Table 1).
In both explored transmission settings, the impact to annual ivermectin co-administration was comparable to that of increas-
ing the treatment frequency of albendazole monotherapy to twice a year (Table 2). Biannual treatment is recommended by the
WHO in high risk settings, if the resources are available — which is not always the case (World Health Organization, 2006).
Even with biannual standalone treatment at a high coverage some heavy infections were projected to remain (Fig. 3). Conse-
quently, even if biannual treatment were feasible, co-administering ivermectin (for both rounds) would still be beneﬁcial in
some settings (Fig. 3 and Table 2).
The assumed level of treatment coverage did not greatly inﬂuence the relative increase in effects gained by co-administering
ivermectin (Supporting Table S2).
The number of worm years and heavy infection case years averted due to preventive chemotherapy was higher in the higher
transmission setting (Table 2). In contrast, the number of prevalent case years averted was often larger in the lower transmissionFig. 2. Projected impact of annual and biannual targeted preventive chemotherapy with and without ivermectin co-administration on the mean worm burden
of T. trichiura. The solid and dotted line pertain to standalone albendazole, and albendazole–ivermectin co-administration respectively. Two different transmission
settings were explored; lower (R0 = 1.25), and higher (R0 = 1.75 — ﬁtted). Results assume 75% treatment coverage of Pre-SAC and SAC. The drug efﬁcacy was
assumed to be 50% for standalone albendazole (Vercruysse et al., 2011a), and 95% when co-administering ivermectin (Speich et al., 2015). Note that those
under ﬁve years of age cannot receive ivermectin and would only be treated with albendazole. ALB; Albendazole, IVM; Ivermectin.
Fig. 3. Projected impact of annual and biannual targeted preventive chemotherapy with and without ivermectin co-administration on the prevalence of heavy
T. trichiura infections in children. The solid and dotted line pertain to standalone albendazole, and albendazole–ivermectin co-administration respectively. Two
different transmission settings were explored; lower (R0 = 1.25), and higher (R0 = 1.75 — ﬁtted). Results assume 75% treatment coverage of Pre-SAC and SAC.
The drug efﬁcacy was assumed to be 50% for standalone albendazole (Vercruysse et al., 2011a), and 95% when co-administering ivermectin (Speich et al.,
2015). Note that those under ﬁve years of age cannot receive ivermectin and would only be treated with albendazole. The results assume the lower intensity
thresholds for heavy infection (presented in Table 1). The corresponding results using the higher intensity threshold are presented in Supporting Fig. S2. ALB;
Albendazole, IVM; Ivermectin.
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proportion of worms are in a small proportion of individuals) (Turner et al., Epub ahead of print). Consequently, at lower worm
burdens, changes in mean worm load will often result in larger changes in prevalence (hence the number of prevalent case years
averted can decrease as the level of transmission increases).
The relative increase in beneﬁts yielded by ivermectin co-administration increased with the level of transmission intensity
(Table 3). In lower transmission settings the relative beneﬁt in terms of averting heavy infections (Table 3) was highly dependent
on the assumed intensity threshold (Table 1) i.e. the higher the intensity threshold, the easier it is to control heavy infections,
and the lower the projected beneﬁt of co-administering ivermectin. When using the higher intensity threshold, the pre-control
prevalence of heavy infections was almost negligible for this transmission setting (hence there was a low beneﬁt of ivermectin
co-administration) (Supporting Fig. S2).3.2. Breaking transmission
When distributing albendazole monotherapy, breaking transmission even in the lower transmission setting was very difﬁcult
without a very high sustained coverage of Pre-SAC and SAC (Fig. 5).
Ivermectin co-administration increased the feasibility of, and decreased the length of time required for, elimination (Fig. 5). As
preventive chemotherapy coverage levels increased, feasibility of elimination improved and was possible in a shorter timeframe.
The projections indicate that expanding treatment to include adults would only very slightly accelerate progress to elimination
(by a maximum of two years). It should be noted that, even with ivermectin co-administration, elimination was often not possible
within this timeframe in settings with high transmission.3.3. Mebendazole–ivermectin co-administration
A standalone treatment of mebendazole was assumed to have slightly higher efﬁcacy compared to standalone albendazole
(Vercruysse et al., 2011a; Levecke et al., 2014a), and therefore it was projected to have a slighter larger impact (Fig. 5 and
Supporting Fig. S4). However, ivermectin co-administration still notably increased the programmatic effectiveness of a
mebendazole-based programme and the general trends remained the same (Supporting Fig. S4). This was found to be particularly
important in the context of achieving elimination — as standalone mebendazole is still insufﬁcient to break transmission in many
settings, despite its higher efﬁcacy (Supporting Fig. S4).
Table 2
Programmatic impact in terms of theworm burden reduced, prevalent case years averted, and heavy infection case years averted, when treatingwith andwithout iver-
mectin co-administration.
Treatment strategy Worm years
averted (per 100)
Prevalent case years
averted (per 100)
Heavy infection case years averted —
lower thresholda (per 100)
Heavy infection case years averted —
higher thresholda (per 100)
Fitted (higher) transmission setting
Standalone albendazole
Annual targeted treatment 24,290 52 55 19
Biannual targeted treatment 35,733 158 78 22
Ivermectin co-administration
Annual targeted treatment 33,653 118 75 22
Biannual targeted treatment 40,981 390 84 23
Lower transmission setting
Standalone albendazole
Annual targeted treatment 8,995 218 12.888 0.512
Biannual targeted treatment 10,055 276 13.353 0.517
Ivermectin co-administration
Annual targeted treatment 10,005 275 13.355 0.517
Biannual targeted treatment 10,858 363 13.538 0.518
Results assume 75% treatment coverage of Pre-SAC and SAC. Two different transmission settings were explored; lower (R0 = 1.25), and higher (R0 = 1.75 —
ﬁtted). The analysis was performed with a ten year time horizon (comparing ten years of standalone treatment to ivermectin co-administration). Note that
those under ﬁve years of age did not receive ivermectin and would only be treated with albendazole.
a The thresholds for heavy infection are presented in Table 1.
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4.1. Controlling morbidity
Though targeting children for preventive chemotherapy with the current monotherapy treatments reduces T. trichiura worm
burdens, the impact on T. trichiura was lower than on A. lumbricoides (despite their similar age intensity proﬁles) (Anderson
et al., 2014, 2015; Truscott et al., 2014, 2015).
In lower transmission settings and at a high coverage of Pre-SAC and SAC, monotherapy was projected to be effective in
controlling heavy infections in children (Fig. 3 and Supporting Fig. S2) — though moderate intensity infections may still remain
and have an impact on health (Fig. 1). However, these simulations indicate that in high transmission settings annual monotherapy
may be insufﬁcient to fully control heavy infections. Co-administering ivermectin increased the projected impact of the pro-
gramme, particularly in high transmission settings (though some heavy infections remained when treatment was given annually).
Increasing the treatment frequency of albendazole monotherapy to twice a year was projected to have an equivalent impact to
that of annual ivermectin co-administration. Biannual treatment is recommended by the WHO in high risk settings, if the re-
sources are available — which is not always the case (World Health Organization, 2006). However, it is also important to recog-
nise that increasing the treatment frequency of preventive chemotherapy results in a notable increase in programmatic costs and
the resources needed for delivery (Turner et al., 2013, 2015a). Furthermore, biannual standalone treatment did not clear all heavy
infections (Fig. 3). Consequently, if biannual treatment were feasible in a certain setting, co-administering ivermectin (for both
rounds) would result in additional beneﬁt (Fig. 3 and Table 2).
These ﬁndings were slightly more striking for programmes distributing albendazole than for mebendazole (as albendazole was
assumed to have a slightly lower efﬁcacy), but the general conclusions apply to both monotherapy treatments.
4.2. Breaking transmission
When using the current standalone treatments, elimination of T. trichiura was projected to be infeasible many settings (Fig. 5).
This has particularly important consequences if STH control programmes shift their goals from control of morbidity to the inter-
ruption of transmission, as it indicates that without a change in approach, many endemic areas will be unable to meet new targets
and treatment will have to be continued (which has important economic implications). Ivermectin co-administration greatly in-
creased feasibility and lowered the timeframe of repeated preventive chemotherapy required for elimination (Fig. 5) — which
could potentially generate programmatic cost savings (Turner et al., Epub ahead of print).
The coverage level of Pre-SAC and SAC was the most inﬂuential on feasibility of elimination. The projections indicate
expanding treatment to adults through community-wide treatment would only very slightly accelerate progress to elimination
in this setting (Fig. 5). The beneﬁt of treating adults for T. trichiura was less than that estimated for A. lumbricoides, and much
less than for hookworm, due to the assumed age proﬁle of infection intensity (derived from a set of ﬁeld studies in St Lucia
(Bundy et al., 1987)) — which determines the proportion of the total worm population in adults (Truscott et al., 2014;
Anderson et al., 2014; Turner et al., 2015b).
In the higher transmission setting our projections indicated elimination may not be feasible with preventive chemotherapy
alone (even with ivermectin co-administration) (Figs. 5 and 6). This highlights the need for complementary control interventions
such as water, sanitation and hygiene (WASH) (Pullan et al., 2014b) and improvements in health education.
Fig. 4. Impact of a child-targeted preventive chemotherapy in terms of heavy case years averted with and without ivermectin co-administration. The bars are strat-
iﬁed by the host age-group (from the bottom up: Infants (0–2 year olds), Pre-SAC (2–5 year olds), SAC (5–15 year olds), and Adults (≥15 year olds)). Results per-
tain to the ﬁtted (higher) transmission setting (R0 = 1.75 — ﬁtted) and assume 75% treatment coverage of Pre-SAC and SAC. The analysis was performed with a
ten year time horizon (comparing ten years of standalone treatment to ivermectin co-administration). The drug efﬁcacy was assumed to be 50% for standalone
albendazole (Vercruysse et al., 2011a), and 95% when co-administering ivermectin (Speich et al., 2015). The results assume the lower intensity thresholds for
heavy infection (presented in Table 1). The corresponding results using the higher intensity threshold are presented in Supporting Fig. S3. ALB; Albendazole,
IVM; Ivermectin.
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Our projections indicate that if ivermectin or another alternative treatment could be given to Pre-SAC, heavy infections would
be further reduced (Fig. 4 and Supporting Fig. S3) and the timeline to elimination would be shorter — at least in settings where
Pre-SAC have a high proportion of the overall worm burden (Bundy et al., 1987) (Fig. 6). This analysis indicates that it would be
advantageous for Pre-SAC to be eligible for any novel treatment strategy for T. trichiura (Albonico et al., 2008), particularly if pro-
grammatic goals shift towards breaking transmission (Fig. 6).4.4. Limitations
Due to the limited availability of data, there remains uncertainty surrounding the parameterisation of the key epidemiological
processes of T. trichiura transmission models. This is particularly true for the strength of the density dependence acting on female
worm fecundity — which requires worm expulsion data to parameterise.Table 3
Sensitivity of the relative increase in effects gained by co-administering ivermectin with albendazole to the transmission setting (in comparison with targeted
albendazole monotherapy).
Transmission
intensity
Worm years
averted
Prevalent case
years averted
Heavy infection case years
averted — lower thresholda
Heavy infection case years
averted — higher thresholda
Higher 39% 126% 36% 15%
Lower 11% 26% 4% 1%
Results pertain to a targeted preventive chemotherapy programme treating Pre-SAC and SAC with 75% treatment coverage. Two different transmission settings
were explored; lower (R0 = 1.25), and higher (R0 = 1.75 — ﬁtted). The analysis was performed with a ten year time horizon (i.e. comparing ten years of
standalone treatment to ivermectin co-administration). Note that those under ﬁve years of age did not receive ivermectin and would only be treated with
albendazole.
a The thresholds for heavy infection are presented in Table 1.
Fig. 5. Number of years of annual treatment to achieve elimination of T. trichiura as a function of coverage of children versus adults. Two different transmission
settings were explored; lower (R0 = 1.25), and higher (R0 = 1.75 — ﬁtted). Note that those under ﬁve years of age did not receive ivermectin and would only
be treated with albendazole. ALB; Albendazole, IVM; Ivermectin. The corresponding results for mebendazole as shown in Supporting Fig. S4. Durations over ten
years were not considered (marked as NA (not achievable)).
184 H.C. Turner et al. / Parasite Epidemiology and Control 1 (2016) 177–187It is important to note that the projections regarding the added beneﬁt of treating Pre-SAC and the limited impact of expanding
mass treatment to include adults are highly dependent on the assumed age proﬁle of infection intensity (Figs. 1 and 6) — which is
used to parameterise the relative exposure of different age groups to eggs in the environment. Though, the absence of alternative
age stratiﬁed intensity datasets from other settings remains an important limitation of this study, the assumed proﬁle and lower bur-
den in adults (Fig. 1) is consistent with the overall pattern found by a recent systematic review of epidemiological surveys of STH in
Southeast Asia (Fig. 7A) (Dunn et al., 2016) and data from a study in Cameron (Mbuh et al., 2012) (Fig. 7B). That said there will be
variations in this infection proﬁle, and mass treatment of adults may be needed in some settings (furthermore pregnant women
(a recognised risk group) may require treatment independent of this (Gyorkos et al., 2012)). More cross-sectional studies that mea-
sure both egg counts and worm burden are required to allow a range of different age proﬁles of infection intensity to be explored in
the sensitivity analysis. It is important to note that converting EPGmeasurements to worm burden is not straightforward and would
require a robust model of diagnostic sensitivity. This is an important area of future research for STH transmission models, as it will
allow signiﬁcantly more data to be used in model parameterization and validation.Fig. 6. Mean intensity of infection in different age groupings (A) and the number of years of annual treatment to achieve elimination of T. trichiura with and with-
out Pre-SAC being eligible for ivermectin co-administration (B). The age proﬁle of infection intensity used to parameterise the model (Fig. 1) is taken from (Bundy
et al., 1987). †Accounting for both the age proﬁle of infection intensity and the assumed demography (Truscott et al., 2014) yields an estimate of 25% of the worms
occurring in Pre-SAC. Results in panel B) pertain to a ﬁtted (higher) transmission setting (R0 = 1.75). Durations over ten years were not considered (marked as NA
(not achievable)). ALB; Albendazole, IVM; Ivermectin.
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lished literature (Chan et al., 1994; Turner et al., 2015a; Medley et al., 1993)). However, it is important to acknowledge that these
thresholds (Table 1) are uncertain, and are likely to be inﬂuenced by a number of host speciﬁc factors such as nutritional status
(Turner et al., Epub ahead of print; Brooker, 2010). These results further highlight that the reduction in prevalence of infection is a
poor effectivenessmetricwhen evaluating the impact of preventive chemotherapy onmorbidity (which is linked to heavy infections).
Because the number of prevalent case years averted is often larger in lower transmission settings (Table 2) thismetric would indicate
it ismore cost-effective to treat in lower compared to higher transmission settings (the opposite towhat is observedwhen usingmet-
rics based on intensity (Turner et al., Epub ahead of print)).
It should be noted that uncertainty surrounds the precise treatment efﬁcacies against T. trichiura — partly due to the limita-
tions of the current widely used diagnostic tool of faecal egg examination (Nikolay et al., 2014). However, the relative increase
in the treatment efﬁcacy when co-administering ivermectin was parameterised based on randomized controlled trials (Knopp
et al., 2010; Speich et al., 2015) and is supported by other studies (Beach et al., 1999; Belizario, 2003).
Furthermore, these projections do not account for any non-compliance to treatment and assume that everyone has an equal
probability of taking each treatment. Consequently, the beneﬁt of increasing the treatment frequency will probably be
overestimated (as it does not account for individuals systematically missing both treatment rounds — which can reduce the
beneﬁt of increasing the treatment frequency (Turner et al., 2014a)).
4.5. Research needs
Ivermectin is currently donated for onchocerciasis and lymphatic ﬁlariasis control (25 Years: The MECTIZANⓇ Donation
Program), but not directly for STH. Consequently, the actual ﬁnancial cost of ivermectin and/or its potential economic value if
it were to be donated for STH needs to be estimated to allow future cost-effectiveness analysis (an important gap for NTDs
(Turner et al., 2014b, 2015a; Lee et al., 2015)).
It is important to consider that the use of ivermectin against T. trichiura will also have additional beneﬁcial effects against
Strongyloides infection (Datry et al., 1994), residual levels of onchocerciasis and lymphatic ﬁlariasis (Ottesen et al., 2008), and
against co-endemic ectoparasites (such as scabies) (Dourmishev et al., 2005; Heukelbach et al., 2004).
Ivermectin co-administration is not the only potential solution for the limited efﬁcacy of the standard treatments against
T. trichiura, and there is ongoing research on other drugs/drug combinations (such as: triple dosing with standalone albendazole
or mebendazole, pyrantel–oxantel (Albonico et al., 2002), oxantel pamoate–albendazole (Speich et al., 2015; Keiser et al., 2014)
and papaya cysteine proteinases (Levecke et al., 2014b)). This analysis indicates it would be advantageous for Pre-SAC to be
eligible for any new treatment combinations. Dynamic transmission models can be useful tools for comparing the impact of
the different alternative drugs/combinations (not only for T. trichiura, but the other STH species as well). This will be important
for gaining a comprehensive understanding of the impact of the different potential drugs on all of the STH.
An important programmatic consideration for treating continuously with drugs that do not effectively clear T. trichiura is the
potential risk of drug resistance developing (Vercruysse et al., 2011b; Olliaro et al., 2011). The use of drug combinations may be
an important method for delaying or avoiding drug resistance (as using drugs with different modes of action can make it harder
for resistance to develop and spread). This aspect should be an important consideration in the evaluation of the various potential
treatment alternatives for T. trichiura (Diawara et al., 2013). As STH programmes expand over the coming years, further research
in methods for detecting resistance and controlling its spread is urgently needed (Vercruysse et al., 2011b; Barda et al., 2015).
A positive ﬁnding of this study is that current lymphatic ﬁlariasis treatment programmes, which include community-wide iver-
mectin–albendazole combination therapy, may be having a large impact on T. trichiura. This is supported by observations in the
ﬁeld (Massa et al., 2009). For this reason, future studies into the impact that scale-down or completion of LF control programmesFig. 7. Observed age proﬁles of T. trichiura infection intensity in Southeast Asia (A) and Southwest Cameroon (B). Panel A contains EPG data from 11 studies (18
areas in four different countries) identiﬁed by a systematic review of epidemiological surveys of STH in Southeast Asia (Dunn et al., 2016) (compared to data from
the St. Lucia study (Bundy et al., 1987)). Panel B reproduces that data provided by a study from Cameroon (Mbuh et al., 2012). EPG: eggs per gramme of faeces.
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programmes move towards elimination.
4.6. Conclusion
Although the current STH programmes providing child-targeted preventive chemotherapy with annual standalone albendazole
or mebendazole reduce T. trichiura worm burdens, the impact for children is much lower compared to what can be seen for the
other STH (Truscott et al., 2014, 2015; Anderson et al., 2014). In addition, these simulations indicate that in high transmission set-
tings the standard treatments may be insufﬁcient to fully control prevalence of heavy infections. Co-administering ivermectin
greatly increased the projected impact of the programme in these high transmission settings, particularly in settings where bian-
nual treatment is not possible.
When using the current standalone treatments, breaking transmission was projected to be infeasible in most settings. Ivermectin
co-administration greatly increased the feasibility of and timeframe for elimination. This has particularly important consequences if
STH control programmes shift their goals to the interruption of transmission. However, the beneﬁt of ivermectin co-administration is
limited by the fact that Pre-SAC are mostly ineligible for ivermectin. It would advantageous for this age group to be made eligible for
any novel treatment strategy against T. trichiura.
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